Literature DB >> 8694551

Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation.

M Plebani1, A Giacomini, L Beghi, M de Paoli, G Roveroni, F Galeotti, A Corsini, C G Fraser.   

Abstract

During cancer monitoring, data on biological and analytical variation are required in order to define the critical difference which provides an objective means to interpret serial values. We evaluated four tumor markers on serial samples collected from healthy subjects and patients. Analytical coefficients of variation (CV(A)), were obtained from "precision profiles" based on the differences between duplicates cumulated from assay runs in the laboratory. We defined the mean intrasubject biological variation (CV(I)) for CA 19-9 and TPA, separately for healthy people and patients; since the differences between the two groups were not statistically significant, we pooled the results and re-evaluated CV(I) in the combined groups (CA 19-9: CV(I) = 15.9%; TPA: CV(I) = 25.7%). In addition, we evaluated CV(I) for CEA (10.9%) and for TPS (25.9%) in patients. We then evaluated the inter-subject biological variations (CV(G)); the calculated indices of individuality for the four markers were less than 0.6 which shows conventional reference values to be of little utility for interpretation. We finally evaluated the critical differences (p < 0.05) for CA 19-9 (CD = 44.7%), for TPA (CD = 72.5%), CEA (CD = 32.7%) and TPS (CD = 72.5%); these are generally applicable since there was no heterogeneity in intra-subject biological variability.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694551

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  The long-term biological variability of fasting plasma glucose and serum fructosamine in healthy Beagle dogs.

Authors:  A L Jensen; H Aaes; L Iversen; T K Petersen
Journal:  Vet Res Commun       Date:  1999-03       Impact factor: 2.459

2.  Biological variation of serum neuron-specific enolase and carbohydrate antigen 724 tumor markers.

Authors:  Shuo Wang; Min Zhao; Runqing Mu; Xin Zhang; Ke Yun; Hong Shang
Journal:  J Clin Lab Anal       Date:  2017-09-19       Impact factor: 2.352

3.  Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 4.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.